MARKET

OSMT

OSMT

Osmotica Pharmaceuticals Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.97
+0.04
+0.67%
After Hours: 6.00 +0.03 +0.50% 17:28 05/29 EDT
OPEN
5.86
PREV CLOSE
5.93
HIGH
6.37
LOW
5.75
VOLUME
321.36K
TURNOVER
--
52 WEEK HIGH
7.97
52 WEEK LOW
2.250
MARKET CAP
351.63M
P/E (TTM)
-1.1724
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OSMT stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 4.000.

EPS

OSMT News

More
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
PR Newswire · 3d ago
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 3d ago
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual Healthcare Conference
GlobeNewswire · 4d ago
Here's What Analysts Are Forecasting For Osmotica Pharmaceuticals plc (NASDAQ:OSMT) After Its First-Quarter Results
Simply Wall St. · 05/15 15:12
3 Biotech Stocks Under $4 With at Least 50% Upside Potential
TipRanks · 05/14 14:31
75 Biggest Movers From Yesterday
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares climbed 88% to close at $4.14 on Wednesday following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/14 08:26
Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
GlobeNewswire · 05/13 22:08
Osmotica Pharmaceuticals PLC (OSMT) CEO Brian Markison on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 01:14

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About OSMT

Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company is focused on progressing Phase III candidates under clinical development Ontinua ER and RVL-1201. It has developed Ontinua ER using its proprietary Osmodex drug delivery system. Ontinua ER has been designated by the FDA as an Orphan Drug in this indication. The Company is conducting a second Phase III clinical trial of RVL-1201 for droopy eyelid. The Company’s promoted products include specialty neurology drugs, such as Lorzone and ConZip for pain management, as well as women's health products, such as Divigel for menopause and the OB Complete family of prescription prenatal dietary supplements. The Company’s non-promoted products portfolio include methylphenidate ER and VERT as well as smaller volume ANDAs and prescription dietary supplements.
More

Webull offers kinds of Osmotica Pharmaceuticals PLC stock information, including NASDAQ:OSMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OSMT stock news, and many more online research tools to help you make informed decisions.